FeesSafety
Pluang+

EssilorLuxottica reports total shares and voting rights as of October 31, 2026, with a 31% voting cap per shareholder.

Company Fundamentals
11 Nov 2026, 00:00 WIB
Na
View Source
Neutral
EssilorLuxottica reports total shares and voting rights as of October 31, 2026, with a 31% voting cap per shareholder.

As of October 31, 2026, EssilorLuxottica disclosed its total number of shares at 464,247,548 and actual voting rights at 458,376,127 after deducting treasury shares. The company enforces a 31% voting rights cap per shareholder, as outlined in its statutes. This update provides transparency on the company's capital structure and voting power distribution, important for shareholders and potential investors to understand control limits within the firm.

EssilorLuxottica's voting rights and share count provide context for readers. For those tracking the Consumer Cyclical sector, 33 of 134 US stocks rose while 100 fell. Notable movers include MBLY at USD 5.57 with a -4.95% change, RENT at USD 2.15 down 4.87%, and CVNA at USD 72.81 down 4.52% with 100% buy orders on Pluang, as of Nov 11, 2026 00:03 WIB.

More News

EssilorLuxottica reports 464 million shares and voting rights as of October 31, 2026, with a 31% voting cap.

EssilorLuxottica reports 464 million shares and voting rights as of October 31, 2026, with a 31% voting cap.

EssilorLuxottica disclosed its share capital and voting rights as of October 31, 2026, reporting 464,247,548 shares outstanding and 458,376,127 real voting rights excluding treasury shares. The company applies a 31% cap on voting rights per sharehold...

Company Fundamentals
Neutral
23 minutes ago
Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...

Bullish
1 hour ago
Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...

Others
Bullish
1 hour ago
New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...

Others
Bullish
2 hours ago
Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

The global nucleic acid labeling market, valued at $1.7 billion in 2025, is projected to grow to $2.8 billion by 2032 at a 7% CAGR. Growth is fueled by advances in genomics, molecular diagnostics, and personalized medicine, with increasing demand for...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App